Detection of signals of abuse and dependence applying disproportionality analysis

European Journal of Clinical Pharmacology

Volumn 71, Issue 2, 2015, Pages 229-236

  Pauly, V ^a   Lapeyre Mestre, M ^b   Braunstein, D ^a   Rueter, M ^b   Thirion, X ^a   Jouanjus, E ^b   Micallef, J ^a,c  

^a AIX MARSEILLE UNIVERSITY   (France)

^b UNIVERSITÉ DE TOULOUSE   (France)

^c TIMONE HOSPITAL   (France)

Author keywords

Disproportionality; Drug abuse; PRR; Signal detection

Indexed keywords

ACAMPROSATE; ALIMEMAZINE; ALPRAZOLAM; AMISULPRIDE; ARIPIPRAZOLE; BACLOFEN; BROMAZEPAM; BUPRENORPHINE; CLOBAZAM; CLONAZEPAM; CLORAZEPATE; CLORAZEPATE DIPOTASSIUM; CODEINE; FLUNITRAZEPAM; KETAMINE; LORAZEPAM; MEPROBAMATE; METHADONE; METHYLPHENIDATE; MORPHINE SULFATE; OXAZEPAM; PARACETAMOL; PAROXETINE; PRESCRIPTION DRUG; PSYCHOTROPIC AGENT; TRIHEXYPHENIDYL; TROPATEPINE; ZOLPIDEM;

ADULT; ALCOHOL CONSUMPTION; ALCOHOLISM; ARTICLE; DATA BASE; DRUG ABUSE; DRUG DEPENDENCE; DRUG SURVEILLANCE PROGRAM; FEMALE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; POPULATION GROUP; PRIORITY JOURNAL; ADDICTION; DRINKING BEHAVIOR; DRUG ADMINISTRATION ROUTE; DRUG SEEKING BEHAVIOR; DRUG UTILIZATION; FACTUAL DATABASE; MIDDLE AGED; PROCEDURES; PSYCHOLOGY; SUBSTANCE ABUSE;

ADULT; ALCOHOL DRINKING; DATABASES, FACTUAL; DRUG ADMINISTRATION ROUTES; DRUG UTILIZATION; DRUG-SEEKING BEHAVIOR; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHOTROPIC DRUGS; SUBSTANCE ABUSE DETECTION; SUBSTANCE-RELATED DISORDERS;

EID: 84922103845     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-014-1783-x     Document Type: Article

References (43)

1. Grundmark B, Holmberg L, Garmo H, Zethelius B (2014) Reducing the noise in signal detection of adverse drug reactions by standardizing the background: a pilot study on analyses of proportional reporting ratios-by-therapeutic area. Eur J Clin Pharmacol 70(5):627-635
2. Montastruc J-L, Sommet A, Bagheri H, Lapeyre-Mestre M (2011) Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Br J Clin Pharmacol 72(6):905-908
3. Salvo F, Raschi E, Moretti U, Chiarolanza A, Fourrier-Réglat A, Moore N et al (2014) Pharmacological prioritisation of signals of disproportionate reporting: proposal of an algorithm and pilot evaluation. Eur J Clin Pharmacol 70(5):617-625
4. Rothman KJ, Lanes S, Sacks ST (2004) The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf 13(8):519-523
5. Waller P, van Puijenbroek E, Egberts A, Evans S (2004) The reporting odds ratio versus the proportional reporting ratio: « deuce ». Pharmacoepidemiol Drug Saf 13(8):525-526
6. Van Puijenbroek EP, Bate A, Leufkens HGM, Lindquist M, Orre R, Egberts ACG (2002) A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf 11(1):3-10
7. Coulter DM, Bate A, Meyboom RH, Lindquist M, Edwards IR (2001) Antipsychotic drugs and heart muscle disorder in international pharmacovigilance: data mining study. BMJ 322(7296):1207-1209
8. Robert E, Rosa F (1983) Valproate and birth defects. Lancet 2(8359):1142
9. Edwards IR (2012) An agenda for UK clinical pharmacology: pharmacovigilance. Br J Clin Pharmacol 73(6):979-982
10. Schwan S, Sundström A, Stjernberg E, Hallberg E, Hallberg P (2010) A signal for an abuse liability for pregabalin - results from the Swedish spontaneous adverse drug reaction reporting system. Eur J Clin Pharmacol 66(9):947-953
11. Beau-Salinas F, Jonville-Béra AP, Cissoko H, Bensouda-Grimaldi L, Autret-Leca E (2010) Drug dependence associated with triptans and ergot derivatives: a case/non-case study. Eur J Clin Pharmacol 66(4):413-417
12. Caster O, Edwards IR, Norén GN, Lindquist M (2011) Earlier discovery of pregabalin's dependence potential might have been possible. Eur J Clin Pharmacol 67(3):319-320
13. Baumevieille M, Miremont G, Haramburu F, Maurain C, Bégaud B (2001) The French system of evaluation of dependence: establishment in a legal system. Therapie 56(1):15-22
14. Pauly V, Frauger E, Pradel V et al (2011) Monitoring of benzodiazepine diversion using a multi-indicator approach. Int Clin Psychopharmacol 26(5):268-277
15. Pauly V, Pradel V, Pourcel L, Nordmann S, Frauger E, Lapeyre-Mestre M et al (2012) Estimated magnitude of diversion and abuse of opioids relative to benzodiazepines in France. Drug Alcohol Depend 126(1-2):13-20
16. Peyriere H, Eiden C, Micallef J, Lapeyre-Mestre M, Faillie J-L, Blayac J-P (2013) Slow-release oral morphine sulfate abuse: results of the postmarketing surveillance systems for psychoactive prescription drug abuse in France. Eur Addict Res 19(5):235-244
17. Moracchini C, Orleans V, Miloudi S, Frauger E, Micallef J, Thirion X et al (2012) General practitioners' contribution to dependence assessment: the OPEMA programme. Therapie 67(4):397-404
18. Thirion X, Micallef J, Barrau K, Djezzar S, Sanmarco JL, Lagier G (2001) Observation of psychoactive substance consumption: methods and results of the French OPPIDUM programme. Eur Addict Res 7(1):32-36
19. Frauger E, Moracchini C, Le Boisselier R, Braunstein D, Thirion X, Micallef J et al (2013) OPPIDUM surveillance program: 20 years of information on drug abuse in France. Fundam Clin Pharmacol 27(6):672-682
20. American Psychiatric Association (Pub.) (2000) Diagnostic and statistical manual of mental disorders, 4th edn - text revision (DSMIV-TR)
21. Pradel V, Delga C, Rouby F, Micallef J, Lapeyre-Mestre M (2010) Assessment of abuse potential of benzodiazepines from a prescription database using « doctor shopping » as an indicator. CNS Drugs 24(7):611-620
22. Casati A, Sedefov R, Pfeiffer-Gerschel T (2012) Misuse of medicines in the European Union: a systematic review of the literature. Eur Addict Res 18(5):228-245
23. Cicero T, Dart C, Inciardi J et al (2007) The development of a comprehensive risk-management program. Pain Med 8(2):157-171
24. Jegu J, Gallini A, Soler P, Montastruc J-L, Lapeyre-Mestre M (2011) Slow-release oral morphine for opioid maintenance treatment: a systematic review. Br J Clin Pharmacol 71(6):832-843
25. Reynaud-Maurupt C, Bello P-Y, Akoka S, Toufik A (2007) Characteristics and behaviors of ketamine users in France in 2003. J Psychoactive Drugs 39(1):1-11
26. AFSSAPS (2002) Usage détourné de kétamine et de tilétamine: modifications règlementaires. [Internet]. Available at: http://ansm.sante.fr/S-informer/Informations-de-securite-Lettres-aux-professionnels-de-sante/Usage-detourne-de-ketamine-et-de-tiletamine-modifications-reglementaires/(language)/fre-FR. Last accessed 16 June 2014
27. Substance Abuse and Mental Health Services Administration-SAMHSA (2010) DAWN, tables 2010. [Internet]. 2010 [cité 14 juin 2013]. Available at: http://www.samhsa.gov/data/DAWN.aspx#DAWN 2010 ED Excel Files - National Tables. Last accessed 16 June 2014
28. Schifano F, Corkery J, Oyefeso A, Tonia T, Ghodse AH (2008) Trapped in the « K-hole »: overview of deaths associated with ketamine misuse in the UK (1993-2006). J Clin Psychopharmacol 28(1):114-116
29. Chen LC, Hashimoto Y, Furuya H, Takekawa K, Kubota T, Hiraoka K (2009) Rapid detection of drugs in biofluids using atmospheric pressure chemi/chemical ionization mass spectrometry. Rapid Commun Mass Spectrom RCM 23(3):333-339
30. Frauger E, Pauly V, Natali F, Pradel V, Reggio P, Coudert H et al (2011) Patterns of methylphenidate use and assessment of its abuse and diversion in two French administrative areas using a proxy of deviant behaviour determined from a reimbursement database: main trends from 2005 to 2008. CNS Drugs 25(5):415-424
31. Lapeyre-Mestre M, Gony, Carvajal A, Conforti A, D'Incau P, Heerdink R et al (2014) A European community pharmacy-based survey to investigate patterns of prescription fraud through identification of falsified prescriptions. Eur Addict Res 20(4):174-182
32. Bruggisser M, Ceschi A, Bodmer M, Wilks MF, Kupferschmidt H, Liechti ME (2010) Retrospective analysis of stimulant abuse cases reported to the Swiss Toxicological Information Centre during 1997-2009. Swiss Med Wkly 140:w13115
33. Morton WA, Stockton GG (2000) Methylphenidate abuse and psychiatric side effects. Prim Care Companion J Clin Psychiatry 2(5):159-164
34. Frances C, Hoizey G, Millart H, Trenque T (2004) Paediatric methylphenidate (Ritalin) restrictive conditions of prescription in France. Br J Clin Pharmacol 57(1):115-116
35. Frauger E, Thirion X, Chanut C, Natali F, Debruyne D, Saillard C et al (2003) Misuse of trihexyphenidyl (Artane, Parkinane): recent trends. Therapie 58(6):541-547
36. AFSSAPS (2012) Commission Nationale des Stupéfiants et des Psychotropes. Compte-rendu de la 96ième réunion du 14 février 2012. Adopté le 19 avril 2012. [Internet]. 2013. Available at: http://ansm.sante.fr/var/ansm-site/storage/original/application/329a70741f497b7a6ea5a8062c8292b9.pdf. Last accessed 16 June 2014
37. Cicero TJ, Ellis MS, Paradis A, Ortbal Z (2011) Role of key informants and direct patient interviews in epidemiological studies of substance abuse. Pharmacoepidemiol Drug Saf 20(3):308-312
38. Bourgine J, Ma LL, Le Boisselier R, Paillet-Loilier M, Albessard F, Lelong-Boulouard V et al (2009) Comparison between analytic and anamnestic data about drug consumption among opiate addicts with substitutes therapy. A feasibility study. Therapie 64(4):269-277
39. Pariente A, Gregoire F, Fourrier-Reglat A, Haramburu F, Moore N (2007) Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias. Drug Saf 30(10):891-898
40. Harpaz R, Dumouchel W, Lependu P, Bauer-Mehren A, Ryan P, Shah NH (2013) Performance of pharmacovigilance signal-detection algorithms for the FDA adverse event reporting system. Clin Pharmacol Ther 93(6):539-546
41. Evans SJ, Waller PC, Davis S (2001) Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 10(6):483-486
42. Bonneterre V, Bicout DJ, de Gaudemaris R (2012) Application of pharmacovigilance methods in occupational health surveillance: comparison of seven disproportionality metrics. Saf Health Work 3(2):92-100
43. Pariente A, Avillach P, Salvo F, Thiessard F, Miremont-Salamé G, Fourrier-Reglat A et al (2012) Effect of competition bias in safety signal generation: analysis of a research database of spontaneous reports in France. Drug Saf 35(10):855-864